Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 9Hyperandrogenism 4Neoplasms 3Skin Diseases 1Sarcoma 1Rare Diseases 1Obesity 1Metabolic Syndrome 1Lymphoma 1Leukemia, Myeloid, Acute 1Inflammation 1Hematologic Neoplasms 1Heart Failure 1Glioblastoma 1Endocrine System Diseases 1Critical Illness 1Cardiovascular Diseases 1Cardiotoxicity 1Breast Neoplasms 1Advanced Malignant Neoplasm 1Acute Kidney Injury 1Acanthosis Nigricans 1

Interventions

Metformin 2Leuprolide 2Collagenases 2Clomiphene 2tremelimumab 1durvalumab 1Temozolomide 1Streptozocin 1Spironolactone 1Specimen Handling 1Radiosurgery 1Radiation 1Propofol 1Prednisone 1Plasma Exchange 1Nivolumab 1Midazolam 1Mercaptopurine 1Melphalan 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Infliximab 1Immunoglobulins 1High-Throughput Nucleotide Sequencing 1Fentanyl 1FANG vaccine 1Cyclophosphamide 1Clomipramine 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rare Diseases × Spironolactone × Clear all
NCT00004311 2005-06-24

Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome

Office of Rare Diseases (ORD)

Phase 2 Completed

Acanthosis Nigricans, Endocrine System Diseases, Polycystic Ovary Syndrome, Skin Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡